Search company, investor...

Founded Year



Option/Warrant - III | Alive

Total Raised


Last Raised

$1.86M | 6 mos ago

About Inscripta

Inscripta develops is a life science technology company that offers digital genome engineering. It generates libraries of designer protein, pathway, or genome variants with trackable mutations and helps researchers to design and track results. The company was founded in 2015 and is based in Boulder, Colorado.

Headquarters Location

5720 Stoneridge Drive Suite 300

Pleasanton, California, 94588,

United States




Expert Collections containing Inscripta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inscripta is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Inscripta Patents

Inscripta has filed 228 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • genetics
patents chart

Application Date

Grant Date


Related Topics




Dietary supplements, Food additives, Carotenoids, Food colorings, Food science


Application Date


Grant Date



Related Topics

Dietary supplements, Food additives, Carotenoids, Food colorings, Food science



Latest Inscripta News

Mekonos Appoints Benjamin Borgo as Chief Operating Officer

Aug 9, 2023

Mekonos Appoints Benjamin Borgo as Chief Operating Officer Search jobs Mekonos Appoints Benjamin Borgo as Chief Operating Officer ALAMEDA, Calif.--(BUSINESS WIRE)-- Mekonos, Inc. , a biotech platform company building the future of cell therapies on a chip, today announced the appointment of Benjamin Borgo, MBA, PhD, as chief operating officer. In this newly created role, he will be responsible for developing and implementing operational strategies to support the growth and success of the business. Dr. Borgo reports to Anil Narasimha, PhD, co-founder, chief executive officer of Mekonos. “We are delighted to welcome Ben to the Mekonos leadership team during this important phase of the company’s growth,” Dr. Narasimha said. “His forward-looking leadership style and operational experience – which includes building highly effective teams and brokering successful industry partnerships and alliances – will be invaluable as we continue to advance our integrated cell-engineering platform.” Dr. Borgo brings to Mekonos more than 10 years’ experience in various biotech submarkets, driving product development and managing business portfolios. Most recently, as vice president of mammalian biology and head of product at Inscripta, Dr. Borgo developed and implemented the strategy for deploying their technology in the mammalian cell engineering market, evaluated early-stage M&A opportunities, and deployed a scalable business model to assure the company’s success. “I am excited to join Mekonos as I strongly believe in its mission to ensure that more patients can benefit from cell and gene therapies,” Dr. Borgo said. “The single greatest challenge in the scalable deployment of these life-saving medicines remains the manufacturing and delivery hurdles. Mekonos’ game-changing solution is the most clearly differentiated and most universally deployable technology that I have seen to date. It will change the playing field substantially and be the core technology that accelerates cell and gene therapy development, versatility and adoption.” Prior to Inscripta, Inc., Dr. Borgo has evaluated investment opportunities and managed strategic alliances within cell and gene engineering markets in roles at multinational biotechnology leaders including Merck KGaA/MilliporeSigma and Agilent Technologies. ​​Dr Borgo also oversaw the commercialization efforts of the flagship instrument developed at Berkeley Lights Inc., and was a co-founder of Nanopore Diagnostics, where he helped drive successful early instrument development and pre-series A funding. Dr. Borgo earned his doctorate in biology and biomedical science and an MBA from Washington University. He obtained a bachelor’s degree in applied mathematics from San Francisco State University. About Mekonos, Inc. Mekonos is an enabling technology company transforming synthetic biology and personalized medicine. The company's ex-vivo delivery platform merges innovations in semiconductor, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in Alameda, CA, is backed by leading investors in both healthcare and technology and was named a 2018 Fierce 15 Startup. For more information, please visit . Contacts

Inscripta Frequently Asked Questions (FAQ)

  • When was Inscripta founded?

    Inscripta was founded in 2015.

  • Where is Inscripta's headquarters?

    Inscripta's headquarters is located at 5720 Stoneridge Drive, Pleasanton.

  • What is Inscripta's latest funding round?

    Inscripta's latest funding round is Option/Warrant - III.

  • How much did Inscripta raise?

    Inscripta raised a total of $441.48M.

  • Who are the investors of Inscripta?

    Investors of Inscripta include Spruce Capital Partners, Foresite Capital, Fidelity Investments, T. Rowe Price, Morgan Stanley and 12 more.

  • Who are Inscripta's competitors?

    Competitors of Inscripta include Mammoth Biosciences.


Compare Inscripta to Competitors

Sherlock Biosciences Logo
Sherlock Biosciences

Sherlock Biosciences provides biotherapeutics research and therapy development services. It leverages engineering biology tools, including clustered regularly interspaced short palindromic repeats (CRISPR) and synthetic biology to create molecular diagnostics that can deliver results for a range of needs. It develops a CRISPR-based method to detect and quantify specific genetic sequences named SHERLOCK and a synthetic biology-based molecular diagnostics platform named INSPECTR. Its instrumentation-free platforms are applicable in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. The company was founded in 2019 and is based in Brighton, Massachusetts.

Mammoth Biosciences Logo
Mammoth Biosciences

Mammoth Biosciences operates as a biotechnology company. It focuses on using its ultra-compact systems to develop therapies, medical applications, and decentralized precision diagnostics. It aims to democratize disease detection with a point-of-care test that allows for rapid and simultaneous detection of multiple conditions. It was formerly known as Apheleia Diagnostics. The company was founded in 2017 and is based in Brisbane, California.

Arbor Biosciences Logo
Arbor Biosciences

Arbor Biosciences is a biotech company specializing in custom, affordable solutions for synthetic biology and NGS target enrichment.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.